Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAROLINA trial of linagliptin versus glimepiride in type 2 diabetes at high cardiovascular risk
NL-OMON43615Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2010
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin with Glimepiride (2 arms). Primary endpoints: Time to first major adverse cardiovascular event, Continuous glucose monitoring glucose variability and 1 more. Started Dec 2010; status: active, not recruiting.
02
Drugs
linagliptinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43615.